Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.

Ceramide is a lipid second messenger derived from the hydrolysis of sphingomyelin by sphingomyelinases (SMases) and implicated in diverse cellular responses, including growth arrest, differentiation, and apoptosis. Defects in the neutral SMase (nSMase) gene Smpd3, the primary regulator of ceramide biosynthesis, are responsible for developmental defects of bone; regulation of ceramide levels have been implicated in macrophage differentiation, but this pathway has not been directly implicated in human cancer. In a genomic screen for gene copy losses contributing to tumorigenesis in a mouse osteosarcoma model, we identified a somatic homozygous deletion specifically targeting Smpd3. Reconstitution of SMPD3 expression in mouse tumor cells lacking the endogenous gene enhanced tumor necrosis factor (TNF)-induced reduction of cell viability. Nucleotide sequencing of the highly conserved SMPD3 gene in a large panel of human cancers revealed mutations in 5 (5%) of 92 acute myeloid leukemias (AMLs) and 8 (6%) of 131 acute lymphoid leukemias (ALLs), but not in other tumor types. In a subset of these mutations, functional analysis indicated defects in protein stability and localization. Taken together, these observations suggest that disruption of the ceramide pathway may contribute to a subset of human leukemias.

[1]  A. Feinberg,et al.  An X Chromosome Gene, WTX, Is Commonly Inactivated in Wilms Tumor , 2007, Science.

[2]  M. Wigler,et al.  Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.

[3]  Y. Hannun,et al.  Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. , 1991, The Journal of biological chemistry.

[4]  Michal Levy,et al.  nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. , 2006, Biochemical and biophysical research communications.

[5]  W. Stoffel,et al.  Concordance of gene genealogies reveals reproductive isolation in the pathogenic fungus Coccidioides immitis , 1998 .

[6]  M. Wigler,et al.  Cloning the differences between two complex genomes , 1993, Science.

[7]  Stefan Fröhling,et al.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. , 2007, Cancer cell.

[8]  Obeid,et al.  Sphingomyelinases in cell regulation. , 1997, Seminars in cell & developmental biology.

[9]  W. Lee,et al.  Human retinoblastoma susceptibility gene: cloning, identification, and sequence , 1987, Science.

[10]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[11]  D. Haber,et al.  DOCK4, a GTPase Activator, Is Disrupted during Tumorigenesis , 2003, Cell.

[12]  Y. Hannun,et al.  Inhibition of Tumor Necrosis Factor-induced Cell Death in MCF7 by a Novel Inhibitor of Neutral Sphingomyelinase* , 2002, The Journal of Biological Chemistry.

[13]  R. Saiki,et al.  A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. , 1988, Nucleic acids research.

[14]  J. Jaffrezou,et al.  Signalling sphingomyelinases: which, where, how and why? , 1999, Biochimica et biophysica acta.

[15]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[16]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[17]  D. Housman,et al.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus , 1990, Cell.

[18]  Y. Hannun,et al.  Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. , 1989, The Journal of biological chemistry.

[19]  A. Karakashian,et al.  Expression of neutral sphingomyelinase‐2 (NSMase‐2) in primary rat hepatocytes modulates IL‐β‐induced JNK activation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  L. Chin,et al.  Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers , 2007, Nature.

[21]  Y. Hannun.  Functions of Ceramide in Coordinating Cellular Responses to Stress , 1996, Science.

[22]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[23]  W. Stoffel,et al.  Neutral sphingomyelinase 2 (smpd3) in the control of postnatal growth and development. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Yusuf A. Hannun,et al.  Biologically active sphingolipids in cancer pathogenesis and treatment , 2004, Nature Reviews Cancer.

[25]  Jacek Bielawski,et al.  Role for Mammalian Neutral Sphingomyelinase 2 in Confluence-induced Growth Arrest of MCF7 Cells* , 2004, Journal of Biological Chemistry.

[26]  W. Stoffel,et al.  Neutral Sphingomyelinase 1 Deficiency in the Mouse Causes No Lipid Storage Disease , 2002, Molecular and Cellular Biology.

[27]  Y. Hannun,et al.  Role for Neutral Sphingomyelinase-2 in Tumor Necrosis Factor α-Stimulated Expression of Vascular Cell Adhesion Molecule-1 (VCAM) and Intercellular Adhesion Molecule-1 (ICAM) in Lung Epithelial Cells , 2007, Journal of Biological Chemistry.

[28]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[29]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[30]  T. Lister,et al.  Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature. , 1992, Leukemia.

[31]  E. Estey,et al.  Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. , 1995, Leukemia.

[32]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[33]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[34]  D. Haber,et al.  The Wilms tumor suppressor WT1 directs stage‐specific quiescence and differentiation of human hematopoietic progenitor cells , 2001, The EMBO journal.

[35]  D. Haber,et al.  Cancer: Drivers and passengers , 2007, Nature.

[36]  M. Bittner,et al.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Jacks,et al.  Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. , 1998, Genes & development.

[38]  J. Testa,et al.  Abnormalities of chromosome 16 in association with acute myelomonocytic leukemia and dysplastic bone marrow eosinophils. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Krönke,et al.  Novel Tumor Necrosis Factor-responsive Mammalian Neutral Sphingomyelinase-3 Is a C-tail-anchored Protein* , 2006, Journal of Biological Chemistry.

[40]  R. Desnick,et al.  Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. , 1991, The Journal of biological chemistry.

[41]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Nature Reviews Cancer.

[42]  C. Bishop,et al.  A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse , 2005, Nature Genetics.

[43]  W. Stoffel,et al.  Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.